Contraception:
Indications for: DEPO-SUBQ PROVERA
Injectable contraception.
Limitations of Use:
Not recommended as a long-term (eg, >2yrs) birth control method unless other options are considered inadequate.
Adult Dosage:
Inject 104mg SC every 3 months (12 to 14 weeks). Give 1st dose within 5 days of onset of normal menses (see full labeling for postpartum).
Children Dosage:
Pre-menarche: not applicable.
DEPO-SUBQ PROVERA Contraindications:
Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease. Breast carcinoma. Significant liver disease. Undiagnosed vaginal bleeding. Pregnancy.
Boxed Warning:
Loss of bone mineral density.
DEPO-SUBQ PROVERA Warnings/Precautions:
May lose significant bone mineral density (BMD). Evaluate BMD with long-term use or in adolescents. Risk for osteoporosis (eg, metabolic bone disease, anorexia, family history). Previous or family history of breast cancer (monitor closely). Ectopic pregnancy. History of depression; monitor for mood changes. Diabetes. Monitor conditions aggravated by fluid retention. Do pretreatment physical exam. Discontinue if jaundice or elevated transaminases, visual disturbances, migraine, or thrombotic disorders occur. Nursing mothers.
See Also:
DEPO-SUBQ PROVERA Classification:
Progestin.
DEPO-SUBQ PROVERA Interactions:
May be antagonized by moderate or strong CYP3A4 inducers (eg, bosentan, efavirenz, etravirine, modafinil, rifampin, carbamazepine, phenytoin, phenobarbital, mitotane, St. John's wort, others); avoid. May reduce bone mass with anticonvulsants, corticosteroids; avoid alcohol, tobacco. May be affected by protease inhibitors, NNRTIs. May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.
Adverse Reactions:
Dysfunctional uterine bleeding, headache, increased weight, amenorrhea, inj site reactions, vaginitis, abdominal pain, UTIs, acne; decreased BMD, anaphylaxis.
How Supplied:
Vials—1, 25; Prefilled syringe (1mL)—1 (w. needles); SubQ (prefilled syringe)—1 (w. needle)
Miscellaneous Ob/Gyn conditions:
Indications for: DEPO-SUBQ PROVERA
Pain due to endometriosis.
Limitations of Use:
Not recommended as a long-term (eg, >2yrs) medical therapy for endometriosis-associated pain unless other options are considered inadequate.
Adult Dosage:
See full labeling. Inject 104mg SC every 3 months (12 to 14 weeks). Give 1st dose within 5 days of onset of normal menses.
Children Dosage:
Pre-menarche: not applicable.
DEPO-SUBQ PROVERA Contraindications:
Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease. Breast carcinoma. Significant liver disease. Undiagnosed vaginal bleeding. Pregnancy.
Boxed Warning:
Loss of bone mineral density.
DEPO-SUBQ PROVERA Warnings/Precautions:
May be used as contraceptive; other hormonal contraceptives: not recommended. May lose significant bone mineral density (BMD). Evaluate BMD with long-term use or in adolescents. Risk for osteoporosis (eg, metabolic bone disease, anorexia, family history). Previous or family history of breast cancer (monitor closely). Ectopic pregnancy. History of depression; monitor for mood changes. Diabetes. Monitor conditions aggravated by fluid retention. Do pretreatment physical exam. Discontinue if jaundice or elevated transaminases, visual disturbances, migraine, or thrombotic disorders occur. Nursing mothers.
DEPO-SUBQ PROVERA Classification:
Progestin.
DEPO-SUBQ PROVERA Interactions:
May be antagonized by moderate or strong CYP3A4 inducers (eg, bosentan, efavirenz, etravirine, modafinil, rifampin, carbamazepine, phenytoin, phenobarbital, mitotane, St. John's wort, others); avoid. May reduce bone mass with anticonvulsants, corticosteroids; avoid alcohol, tobacco. May be affected by protease inhibitors, NNRTIs. May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.
Adverse Reactions:
Dysfunctional uterine bleeding, headache, increased weight, amenorrhea, inj site reactions, vaginitis, abdominal pain, UTIs, acne; decreased BMD, anaphylaxis.
How Supplied:
Prefilled syringe—1 (w. needle)
